Abstract Experimental and epidemiological studies have suggested that the phytoestrogen enterolactone is associated to biological mechanisms that may have positive effects on breast cancer development. In a recent study based on American breast cancer patients, high intakes of lignans, the precursor of enterolactone, was found related to lower mortality. The aim of this study was, for the first time, to evaluate if prediagnostic plasma levels of enterolactone were associated to mortality in women diagnosed with breast cancer. Among 24,697 postmenopausal women included into a Danish cohort between 1993 and 1997, 424 developed breast cancer before December 31, 2000. Enterolactone levels were measured in baseline blood samples and related to mortality by Cox proportional hazard models. During a median of 10 years after breast cancer diagnosis, 111 women died (80 from breast cancer). When comparing women with enterolactone levels above the median ([20.5 nmol/l) to those with lower levels, decreased hazard rates (HR) were seen for both all-cause mortality (HR: 0.47; 95% confidence interval: 0.32-0.68) and breast cancer mortality (HR: 0.56; 95% confidence interval: 0.36-0.87). Higher prediagnostic plasma levels of enterolactone were found related to lower mortality among breast cancer patients.
Introduction
Women treated for breast cancer contribute a large proportion of cancer survivors [1] and identification of lifestyle factors that might improve prognosis for this patient group has achieved considerable interest [2] . Intake of plant foods (including fruits, vegetables, whole grain cereals, and legumes) is one of the factors that has been hypothesized as associated to improved breast cancer outcome [3] , and a class of components receiving special interest within this group is phytoestrogens [4] . In Nordic diets, lignans, originating primarily from whole-grain cereals and fiber-rich vegetables [5] , constitute the largest phytoestrogen intake [6] . Lignan products are mainly found as enterolactone in mammalian biofluids from feces, plasma, and urine, and the concentrations are determined primarily by the intake of dietary precursors and the capacity of the intestinal microflora to convert plant lignans to enterolignans [7] . Experimental studies have suggested high intakes of lignans and/or high concentrations of enterolactone to be related to advantageous mechanisms in breast cancer development, including reduction of tumor growth and metastasis [8, 9] , inhibition of aromatase [10] , and modification of steroid hormone metabolism [11] . High dietary intakes of lignans and high blood or urine levels of enterolactone have previously been related to decreased incidence of breast cancer although the literature is not consistent [12] . The influence of lignans on breast cancer prognosis has not been reported until recently, where a study based on American women found a high dietary intake of lignans to be associated with decreased mortality (both total and breast cancer specific) among postmenopausal but not premenopausal women [13] .
Estimation of dietary intake of lignans is based on dietary information from food frequency questionnaires (FFQs) and information on lignan content from food databases. The quality of the exposure information is consequently limited because of incorrect recall among study participants, the ability of the FFQ to estimate intake of lignan-containing foods, and the ability of the food database to precisely estimate contents of lignans in the standard food items obtained by the FFQ. Usage of plasma levels of enterolactone as a biomarker for lignan intake may be a better alternative for exposure assessment, and as an objectively assessed biomarker, this diminishes the errors ascribed to recall, FFQ, and food databases [14] . The aim of this study was to evaluate whether prediagnostic plasma levels of enterolactone were associated to breast cancer-specific and all-cause mortality among 424 postmenopausal breast cancer patients originating from a prospective cohort study.
Materials and methods

Cohort
The ''Diet, Cancer and Health'' study is a prospective cohort study, established with the primary aim of studying the etiological role of diet on cancer risk. Between 1993 and 1997, 79,729 Danish women aged 50-64 and without previous cancer diagnoses were invited to participate in the study. A total of 29,875, corresponding to 37% of those invited, were enrolled into the cohort. A detailed description of the cohort, including socioeconomic factors associated to nonresponse, has been published previously [15] . The mortality rates for the cohort participants have since baseline been considerably lower (approximately 50%) compared to the nonresponders; this is, however, mainly because of other causes than breast cancer. Also when compared to the entire Danish population, the age-adjusted mortality rates are lower among cohort participants.
The ''Diet, Cancer and Health'' study and the present substudy were approved by the Regional Ethical Committees on Human Studies in Copenhagen and Aarhus and by the Danish Data Protection Agency.
All cohort members attained one of two established study centers, and each participant filled in a FFQ and a lifestyle questionnaire. The lifestyle questionnaire included questions about reproductive factors, health status, social factors, and lifestyle habits. From this questionnaire, we obtained information about school education (short B7 years; medium 8-10 years; or long [10 years) and use of hormone replacement therapy (HRT; use at baseline yes/ no). Intake of alcohol was obtained from the FFQ. Anthropometric data were obtained by professional staff members. Body mass index (BMI) was calculated as weight (kg) per height (m) squared.
In the study centers, 20 ml of blood (nonfasting, collected in citrated and plain Venojects) was drawn from each participant. The samples were spun and divided into 1-ml tubes of plasma, serum, red blood cells, and buffy coat. All samples were processed and frozen within 2 h at -20°C. At the end of the day of collection, all samples were stored in liquid nitrogen vapor (maximum temperature, -150°C).
Of the initial 29,875 women, we excluded 326 who later were reported to the Danish Cancer Registry with a cancer diagnosed before the visit to the study clinic. In addition, 8 women were excluded from the study because they did not fill in the lifestyle questionnaire. Because the present analysis aimed at women who were postmenopausal at study entry, we further excluded 4,844 women, including 4,798 who were considered premenopausal because they had reported at least one menstruation \12 months before entry and no use of HRT, 9 women who gave a lifetime history of no menstruation, and 37 women who did not answer the questions about current or previous use of HRT, leaving 24,697 postmenopausal women for study.
Cohort members were identified from their unique personal identification number, which is allocated to every Danish citizen by the Central Population Registry. All the postmenopausal cohort members were linked to the Central Population Registry to obtain information on vital status and emigration. Information on cancer occurrence among cohort members was obtained through record linkage to the Danish Cancer Registry, which collects information on all cases of cancer diagnosed in Denmark [16] . Linkage was done by use of the personal identification number and follow-up was nearly complete (99.8%). Each cohort member was followed up for breast cancer occurrence from date at entry, that is, date of visit to the study center until the date of diagnosis of any cancer (except for nonmelanoma skin cancer), date of death, date of emigration, or December 31, 2000, whichever came first. Incident breast cancer was diagnosed in 434 women during the follow-up period. Of these, 10 were excluded because of lack of blood sample, leaving 424 breast cancer cases for study. The 424 women diagnosed with breast cancer before end of 2000 were linked to the Danish Death Certificate Registry to obtain information about date and cause of death. All cases (100% follow-up) were followed from date of diagnosis (between baseline and end of 2000) until death or December 31, 2008 .
A clinical registry exclusively about breast cancer also exists in Denmark and information on estrogen receptor a (ERa) status was obtained by linkage with the Danish Breast Cancer Co-operative Group, which holds records on a range of details for approximately 90% of all breast cancers diagnosed in Denmark [17] . A standardized immunohistochemical method was used in all medical centers. The cutoff level used to define positive ERa status was C10% positive cells. Information on ERa status was registered for 391 (92%) breast cancer cases, of these 302 women were diagnosed with ERa-positive tumor and 89 with ERa-negative tumor.
Biological analysis
The analytical procedure for time-resolved fluoroimmunoassay of enterolactone in plasma [18, 19] is briefly as follows. A 200-ll aliquot of plasma was mixed with 200 ll b-glucuronidase and sulfatase in acetate buffer and incubated overnight at 37°C. Diethyl ether was used to extract unconjugated enterolactone after hydrolysis. The hydrolyzed extract in buffer was then pipetted into prewashed goat antirabbit IgG microstrips. Simultaneously, antiserum (dilution 1:250,000) in bovine serum albumin Tris buffer and EU-labeled enterolactone (dilution 1:400,000) were added into micro strips. After incubation and shaking of the strips slowly in a DELFIA plate washer (Wallac, Turku, Finland) at room temperature for 90 min, the strips were washed with a DELFIA plate washer (Wallac). Subsequently, DELFIA enhancement solution (Wallac) was added to each well, and the strips were shaken slowly for an additional 5 min. Fluorescence was read in a DELFIA Victor multilable counter (Wallac). Duplicate control plasma samples were processed through the procedure for each batch and placed at the beginning and end of the plates. The concentration of enterolactone in the control plasma was 19.7 nmol/l, and the intra-and inter-assay coefficients of variation were less than 10%. The results of a previous study [20] further showed that the assay's coefficients of variation were virtually independent of the concentration of enterolactone in plasma in the range 0-140 nmol/l.
We used plasma levels of enterolactone to measure exposure, because this biomarker is considered more stable than urinary excretion because of possible enterohepatic recirculation [21] . The plasma concentration is relatively constant within an individual, with a reliability constant of 0.55 during a 2-year period [22] .
Statistical methods
Analyses of the relations between baseline plasma levels of enterolactone and mortality were based on Cox proportional hazard models using follow-up as the time axis and stratifying by age at diagnosis in 5-year intervals. The associations were evaluated with and without adjustment for baseline values of alcohol intake (continuously) and use of HRT at blood sampling (yes/no). Furthermore, tumor grade at diagnosis (I, II, III, or nonductal carcinoma) was included into the models. BMI and education were also evaluated as potential confounders but were found unrelated to the endpoints of interest and therefore not included because of the relatively limited statistical power. Besides tumor grade, the clinical parameters tumor size (mm) and tumor positive axillary lymph nodes (yes/no) were evaluated in the model. In a multivariate model, tumor grade was, however, the only clinical tumor parameter significantly associated to mortality during follow up, and to preserve statistical power, only this parameter was included into the model.
Plasma levels of enterolactone were included into the model as both a linear (per 20 nmol/l) and a dichotomized (below or above the median; 20.5 nmol/l) variable. Before entering plasma levels of enterolactone and alcohol intake linearly into the model, the linearity of the associations was evaluated by linear splines with three boundaries placed at the quartile cutoff points. None of the associations showed signs of deflection or threshold values.
Unadjusted Kaplan-Meier curves were used to examine differences in all-cause and breast cancer mortality for enterolactone levels below or above the median. The survival curves were not adjusted for the potential confounders (including age at diagnosis) using the mean of covariates method because of the limitation of having a large number of dichotomous variables [23] . The included covariates were found to be essentially without impact on the hazard estimates in the Cox model and it was therefore regarded a minor problem to present unadjusted KaplanMeier curves.
Two-sided 95% confidence intervals (95% CI) for the hazard rates (HR) were calculated on the log HR scale. SAS (release 9.1) was used for statistical analyses.
The association between plasma levels of enterolactone and incidence of breast cancer has previously been reported based on these 424 breast cancer cases and a corresponding number of controls [24] .
Results
The 424 breast cancer cases were followed for a median of 10 years during which 111 died and of those, 80 had breast cancer as the primary cause of death. Table 1 shows the descriptive characteristics of the breast cancer cases at cohort baseline and breast cancer diagnosis according to vital status. Compared to women who died during the follow-up period, women alive by December 31, 2008 seemed to have higher plasma levels of enterolactone at baseline, more often have low (grade I) than high (grade III) tumor grade, more often be diagnosed with an ER-positive tumor, were more often HRT users at baseline, had a smaller tumor, and were more likely to be free of positive lymph nodes at diagnosis. No clear differences were seen for age at diagnosis, alcohol intake, BMI, or length of school education.
When assessed as a linear variable, a higher level of enterolactone was associated to lower all-cause mortality (HR: 0.82; 95%CI: 0.70-0.95) per 20 nmol/l increment ( Table 2 ). The tendency was the same for breast cancerspecific mortality (HR: 0.87; 95% CI: 0.75-1.03) per 20 nmol/l increment, although the HR did not reach statistical significance. Adjustment for covariates barely affected the associations.
When stratifying the women according to median levels of enterolactone, the hazard of both breast cancer-specific and total mortality was about 50% lower among the breast cancer patients with enterolactone levels above the median (P = 0.01 and P \ 0.0001, respectively) when compared to women with enterolactone levels below the median. Stratifying according to ER status of the breast tumor did not indicate that the effect of enterolactone differed between these two clinical subtypes. The statistical strength for evaluating especially ER-negative breast cancer was, however, very limited. Figure 1 shows Kaplan-Meier plots for women above or below the median enterolactone level. The plots demonstrate that the lower mortality, both breast cancer-specific and all-cause, among those with the highest enterolactone levels was evident during the entire follow-up period. 
Discussion
In summary, higher prediagnostic plasma levels of enterolactone were found associated to lower mortality (both breast cancer-specific and all-cause) among postmenopausal women. Strengths of this study include its prospective design, relatively long follow-up period, and objective assessments of both exposure and endpoint. The major limitations concern the limited statistical power and potential imprecision of the biomarker [25] . That high plasma levels of enterolactone may be related to improved survival among breast cancer patients is in accordance with the only previously published study [13] . The study by McCann and colleagues found that postmenopausal women with high prediagnostic dietary intakes of lignans, the precursor of enterolactone, had lower risk of dying during approximately 7 years of follow-up. No association was seen among premenopausal women [13] . Also evidence from experimental studies supports that high intake of lignans resulting in high plasma levels of enterolactone may be associated to improved prognosis among breast cancer patients [8] [9] [10] [11] .
Plasma levels of enterolactone are primarily determined by two factors: lignan intake and the efficiency of intestinal bacteria to convert plant lignans to enterolignans [26] . In the previously published study [13] , only lignan intake was considered. Anticipating that enterolactone is the biologically active form, plasma levels of enterolactone may be considered as superior to lignan intake as exposure measurement. Still, the sources of lignans are very relevant to consider. In the study by McCann and colleagues, dark bread, peaches, coffee, broccoli, and winter squash were the main sources [13] , and in this study, whole-grain rye bread, oatmeal, and cabbages were the primary dietary sources associated to plasma levels of enterolactone [27] .
The primary lignan sources in both studies are whole grain and it is highly interesting if this food group, that has been ascribed many other positive health effects [28] [29] [30] , may also be related to survival among breast cancer patients.
When comparing the study of McCann et al. to the present study, it must be taken into account that enterolactone is known to reflect other factors than just lignan intake. Lignan intake is associated to enterolactone levels, but other factors such as body weight, smoking, and frequency of bowel movements are known to modulate the relation between the two [31] . With a reliability constant of 0.55 during a 2-year period [22] , a single plasma measurement of enterolactone can be considered a reasonable exposure assessment for use in epidemiological studies, although some degree of impressions affects the results. Such errors are, however, by definition most likely unsystematic and will thus affect the estimates toward unity.
An important aspect to consider regarding both this study and the study by McCann and colleagues is that both measure exposure (plasma levels of enterolactone and intake of lignans) before breast cancer diagnosis. The studies are, consequently, not able to determine if high plasma levels of enterolactone and/or high intake of lignans after breast cancer diagnosis are related to improved survival. Results from these two studies must therefore primarily be regarded as suggestive of that intake of lignans and/or blood levels of enterolactone may hold preventive effects with regard to breast cancer survival. Several enterolactone measurements in blood samples obtained before and after diagnosis are needed if a causal association is to be pointed. Enterolactone levels and/or lignan intake may simply be markers of a generally healthy diet and/or lifestyle that are related to improved general health. Further studies are needed to consider this aspect. In conclusion, we found higher prediagnostic levels of enterolactone to be related to lower mortality among breast cancer patients. Future studies with better statistical strength are needed to confirm our findings. Adlercreutz 
